vx-745 has been researched along with alvocidib in 4 studies
Studies (vx-745) | Trials (vx-745) | Recent Studies (post-2010) (vx-745) | Studies (alvocidib) | Trials (alvocidib) | Recent Studies (post-2010) (alvocidib) |
---|---|---|---|---|---|
58 | 1 | 35 | 627 | 66 | 204 |
Protein | Taxonomy | vx-745 (IC50) | alvocidib (IC50) |
---|---|---|---|
Chain A, Protein (glycogen Phosphorylase) | Oryctolagus cuniculus (rabbit) | 1 | |
Glycogen synthase kinase-3 beta | Sus scrofa (pig) | 0.36 | |
[Tau protein] kinase | Sus scrofa (pig) | 0.36 | |
Cyclin-T1 | Homo sapiens (human) | 0.0243 | |
Cyclin-K | Homo sapiens (human) | 1.37 | |
Serine/threonine-protein kinase D3 | Homo sapiens (human) | 8 | |
G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.1571 | |
G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.36 | |
Glycogen phosphorylase, muscle form | Oryctolagus cuniculus (rabbit) | 1.2 | |
Epidermal growth factor receptor | Homo sapiens (human) | 7.6 | |
Vitamin K-dependent protein C | Homo sapiens (human) | 0.1429 | |
Protein kinase C gamma type | Homo sapiens (human) | 8 | |
Protein kinase C beta type | Homo sapiens (human) | 8 | |
Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.4 | |
Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.1159 | |
Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.1589 | |
G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.1464 | |
G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 0.2067 | |
Protein kinase C alpha type | Homo sapiens (human) | 6.2667 | |
Glycogen synthase kinase-3 beta | Rattus norvegicus (Norway rat) | 0.185 | |
Cyclin-A2 | Homo sapiens (human) | 0.3441 | |
Dual specificity protein kinase CLK1 | Mus musculus (house mouse) | 1.3 | |
G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.1837 | |
Protein kinase C eta type | Homo sapiens (human) | 8 | |
G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.2249 | |
Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.2367 | |
G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.1 | |
G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.1983 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.4 | |
Protein kinase C iota type | Homo sapiens (human) | 8 | |
Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.525 | |
Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.6517 | |
Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.3365 | |
Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0209 | |
Cyclin-H | Homo sapiens (human) | 0.3413 | |
CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.514 | |
Cyclin-A1 | Homo sapiens (human) | 0.785 | |
Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.1572 | |
Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.1747 | |
Cyclin homolog | Herpesvirus saimiri (strain 11) | 0.185 | |
Protein kinase C epsilon type | Homo sapiens (human) | 5.4933 | |
Protein kinase C theta type | Homo sapiens (human) | 8 | |
Protein kinase C zeta type | Homo sapiens (human) | 8 | |
Protein kinase C delta type | Homo sapiens (human) | 5.63 | |
Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.1765 | |
Serine/threonine-protein kinase D1 | Homo sapiens (human) | 8 | |
Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Rattus norvegicus (Norway rat) | 0.3 | |
G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.1571 | |
Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 0.2067 | |
Cyclin-dependent kinase 12 | Homo sapiens (human) | 1.37 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; LĂ©lias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Russu, WA; Shallal, HM | 1 |
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
4 other study(ies) available for vx-745 and alvocidib
Article | Year |
---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |